A Phase I/II Study of the Effect of Intravenous Anti-IL-5 (Mepolizumab) SB 240563 on the Outcome and Management of Hypereosinophilic Syndromes

NCT00266565 Phase 1/Phase 2 COMPLETED

Toxicity of anti-IL-5

Details

Lead sponsor	Children's Hospital Medical Center, Cincinnati
Phase	Phase 1/Phase 2
Status	COMPLETED
Enrolment	24
Start date	2001-12
Completion	2005-04

Conditions

• Hypereosinophilic Syndromes
• Eosinophilic Gastroenteritis
• Churg-Strauss Syndrome
• Eosinophilic Esophagitis

Interventions

• Mepolizumab

Primary outcomes

• To assess the toxicity of anti-IL-5 in patients with hypereosinophilia — 28 weeks

Countries

United States